Austrian biotech plans Zika vaccine clinical trials in 12 months

12 July 2016 - 14:00 By REUTERS

An Austrian biotech company working with the Institut Pasteur said on Tuesday it planned to start clinical trials with an experimental Zika vaccine in the next 12 months, marking a further acceleration of research in the field.Themis Bioscience has signed a licence deal with the French research institute giving it extensive rights to the Zika vaccine candidate, which is based on established measles vaccine technology.

This article is reserved for Sunday Times subscribers but, for a limited time, is free to read on our newly relaunched website.

To access the article, you only need to register – it’s quick and free. Already registered? Simply sign in below.

If you’ve already registered on the BusinessLIVE, Business Day, Financial Mail or Rand Daily Mail websites? Sign in with the same details.

Note: Login details from the former TimesLIVE/Sunday Times website are no longer valid. Please register again.



Questions or problems? Email helpdesk@timeslive.co.za or call 0860 52 52 00.